

# Promoting Interoperability – The Illinois Prescription Monitoring Program



# INTRODUCTION

- ILHITREC and CHITREC, in collaboration with the Department of Human Services, will discuss the Illinois Prescription Monitoring Program for public health reporting under the Medicaid Promoting Interoperability Program (formerly "Meaningful Use"). Sam Ross, CHITREC, will be the primary speaker in collaboration with Brenda Simms, ILHITREC, to explain requirements of the specialized registry measure.
- Stan Murzynski, IT and Edward Dowllar, MU Coordinators from ILPMP will present information about integrating your EHR to use the service for querying patient prescription history. The Illinois Prescription Monitoring Program (PMP) is an electronic tool that collects information on controlled substance prescriptions, schedules II, III, IV and V. This data is reported on a weekly basis by retail pharmacies dispensing in Illinois.

# DISCLAIMER

- The target audience of this presentation is Eligible Providers, but some references may be made related to Eligible Hospitals.
- This webinar is based on official guidance provided by the Centers for Medicare and Medicaid Services (CMS) and the Office of the National Coordinator (ONC), experiences from CHITREC, ILHITREC, and The Illinois Prescription Monitoring Program (ILPMP),
- This presentation was prepared as a tool to assist providers enrolled in the Promoting Interoperability Program administered by CMS. The tools presented today, are based on specific guidelines available at the time of the Webinar. The ultimate responsibility for compliance, submission and response to any remittance from CMS rests with the provider. CMS policy changes frequently. It is highly recommended that providers and their designee review rules and regulations frequently.



# Agenda

- ILPMP Background
- ILPMP as a Specialized Registry for EHR Incentive Program
- Active Engagement with ILPMP
- Additional Info
- Q&A



# Presenter Goals

At the end of this presentation you should be able to:

- Recognize the purpose and benefits of the ILPMP
- Know how ILPMP fits into the EHR Incentive Program
- Understand requirements of engaging with ILPMP for Promoting Interoperability (formerly “Meaningful Use”) public health reporting



# **ILPMP Background**





# Prescription Drug Monitoring Programs

- Track eRx and dispensing data from pharmacies and providers
- Utilized by 49 states, DC + Guam to reduce drug abuse (schedules II-V)
- Access to PDMP may be available to providers, pharmacists, law enforcement, licensing/regulatory boards, Medicaid, coroners, research



# Illinois Prescription Monitoring Program

- Goal: assist prescribers and dispensers in effective treatment
- Voluntary and free, 24/7 access, available for mobile devices
- View prescriptions dispensed under DEA number
- Includes brief intervention form and link to treatment centers
- Supports integration with EHR, which is required for the EHR Incentive Program (not enough to use ILPMP website)



# Illinois Public Act 100-0564

- Beginning 1/1/18, prescribers of controlled substances must be registered with ILPMP
- Must document attempt to query patient information from ILPMP before prescribing controlled substance
- Requires EHR connectivity with the PDMP by 2021 (Sec. 316, Line 22)



# **Specialized Registries for the EHR Incentive Program**



# Objective 10: Public Health Reporting

- Medicaid Promoting Interoperability (formerly “Meaningful Use”) Objective 10 requires public health reporting
- Objective 10:
  - “The EP is in *active engagement* with a public health agency to submit electronic public health data from CEHRT except where prohibited and in accordance with applicable law and practice.”
  - Measure 1: Immunization Registry
  - Measure 2: Syndromic Surveillance
  - Measure 3: Specialized Registry - **ILPMP falls under this measure**
- Stage 2 in 2018 requires two measures (may report on measure 3 twice)

# Objective 10, Measure 3: Specialized Registry

- To meet the measure, the EP must attest YES to being in *active engagement* to submit data to a specialized registry
- Exclusions: Any EP meeting at least one of the following criteria may be excluded from the specialized registry reporting measure if the EP-
  - ~~Does not diagnose or treat any disease or condition associated with or collection of relevant data that is required by a specialized registry in their jurisdiction during the EHR Reporting Period~~
  - ~~Operates in a jurisdiction for which no specialized registry is capable of accepting electronic transactions~~
  - ~~Operates in a jurisdiction where no specialized registry for which the EP is eligible has declared readiness to receive electronic transactions~~
- No Exclusion for Measure 3 in Illinois means you *must* meet active engagement with a specialized registry unless you are actively engaged with both immunization **AND** syndromic

# Active Engagement: Option 1

- **Completed Registration to Submit Data:**
  - The EP registered to submit data with the PHA within 60 days after the start of the EHR reporting period
  - EP is awaiting an invitation from the PHA or CDR to begin testing and validation
- Option 1 is enough to meet the measure for 2018 only

# Active Engagement: Option 2

- **Testing and Validation:**
  - The EP is in the process of testing and validation of the electronic submission of data
  - Providers must respond to requests from the PHA or, where applicable, the CDR within **30 days**
  - Failure to respond **twice** within an EHR reporting period would result in the provider not meeting the measure
- Option 2 is enough to meet the measure for 2018 only

# Active Engagement: Option 3

- **Production:**
  - The EP has completed testing and validation of the electronic submission and is electronically submitting production data to the PHA or CDR.
- **Production data**
  - Refers to data generated through clinical processes involving patient care
  - It is used to distinguish between data and “test data” which may be submitted for the purposes of enrolling in and testing electronic data transfers.
- Option 3 meets measure for 2018 and future years if remaining in production



# **Active Engagement with ILPMP**





# Registration of Intent

- Register at MURS system (<https://murs.Illinois.gov>)

- Select “Yes” to ILPMP:

**What Public Health System are you testing for:**

ICARE (Illinois Immunization Registry) - Immunization Data Reporting:	<input type="radio"/> Yes	<input type="radio"/> No
ELR (Illinois Disease Surveillance System) - Notifiable Lab Reporting:	<input type="radio"/> Yes	<input type="radio"/> No
ISSS (Illinois Syndromic Surveillance System) - Syndromic Data Reporting:	<input type="radio"/> Yes	<input type="radio"/> No
ISCR (Illinois State Cancer Registry) - Cancer Data Reporting:	<input type="radio"/> Yes	<input type="radio"/> No
ILPMP (Illinois Prescription Monitoring Program) - Prescription Data Reporting:	<input checked="" type="radio"/> Yes	<input type="radio"/> No

- Identify technical contact (receives follow-up with details on connecting EHR):

**Technical (IT) Contact Person**

* Name	<input type="text"/>
* Position	<input type="text"/>

# Registration Confirmation

- Immediately receive email from [dph.murs.contact@Illinois.gov](mailto:dph.murs.contact@Illinois.gov)
- Maintain for audit records

To: [REDACTED]

[REDACTED] W. Chicago Ave.  
Chicago, 60622

From : Illinois Department of Public Health

Date: 11/8/2017

Subject : Meaningful Use Stage 2 Registration of Intent Confirmation

Re :1194756908

This memo confirms your registration for Meaningful Use Stage 2

IPMP (Illinois Prescription Monitoring Program). For questions: [DHS.PMP@Illinois.gov](mailto:DHS.PMP@Illinois.gov)

This registration places you in the Active Engagement Status: Option 1 Completed registration to Submit Data. Additional information about satisfying MU Modified Stage 2 and Stage 3, Per, 8016742 is here: (<https://www.federalregister.gov/documents/2015/10/16/2015-25595/medicare-and-medicaid-programs-electronic-health-record-incentive-program-stage-3-and-modifications>)

# Pre Connection/Testing

- Receive invitation from
  - [DHS.PMP@Illinois.gov](mailto:DHS.PMP@Illinois.gov)
  - [Edward.dowllar@Illinois.gov](mailto:Edward.dowllar@Illinois.gov)
  - [Craig.berberet@Illinois.gov](mailto:Craig.berberet@Illinois.gov)
  - [Stanley.Murzynski@Illinois.gov](mailto:Stanley.Murzynski@Illinois.gov)
- A meeting is set up with Logicoy to discuss possible connection solutions
  - Restful based NCPDP
  - SOAP based PMIX
  - FHIR
- Partner with CEHRT vendor to establish interfacing with Logicoy
  - Logicoy can provide assistances with this including premade EHR interfaces in some instances
  - CEHRT vendor contact can participate as well
- Send test data
- Go Live!

# Production

http://ecdevehrweb.adbcs.blessinghospital.com/ - Allscripts - Windows Internet Explorer provided by Blessing Health System

Provider 1 | Break Link | Hide VTB | Tools | Help | Lock | Logoff

Chart\$ | Daily | Worklist | Task List | Documents | Clinical Desktop | Note | Diagnosis | Visit Charges | Procedure Charges | Encounter Form | Appointments | Patient Lists | I-Learn | ILPMP

**Baggins, Bilbo** | Allergies: Unknown | Security: No Restricted Data | FYI: FYI | AKA: Bilbo | MRN: 1476740  
 Select Patient | DOB: 12/26/1959 | PCP: Beth, Timothy J | Pri Ins: | W Phone: | Other2: | Age: 56 Years | H Phone: (217)222-5252 | Sex: M | Directives:

No patient found

### ILPMP Results

First Name:  Last Name:  Birth Day:  /  /

Patient Name	Date of Birth	Date Filled	Label Name	Strength	Metric Qty/Days Supply	Payment Type	Pharmacy Name/City	Prescriber Name
Bilbo Baggins	1959-12-26	2016-01-12	HYDROCODONE-ACETAMINOPHEN	5MG-325MG	30/30	N/A	MedPlus/BLR	Dr. Johnson
Bilbo Baggins	1959-12-26	2015-11-24	TESTOSTERONE CYPIONATE	200MG/ML	10/30	Private Pay	MedPlus/BLR	Dr. Johnson
Bilbo Baggins	1959-12-26	2014-10-04	HYDROCODONE-ACETAMINOPHEN	10MG-325MG	20/5	Private Pay	MedPlus/BLR	Dr. Johnson

# Production

## Illinois Board of Pharmacy

320 W. Washington, 3<sup>rd</sup> Floor  
Springfield, IL 62786-0001  
Phone (217) 782-8556  
Fax (217) 782-7645  
URL: <http://www.idfpr.com>

2013-01-22

line1  
line2

The Illinois Prescription Monitoring Program has identified:

bilbo baggins (DOB: 1959-12-26)

as one of your patients. This person appears to be obtaining controlled substance prescriptions of the same or similar nature from multiple practitioners and multiple pharmacies. We have developed no conclusions or judgments on the basis of this information; however, in the event this observation should concern you, we suggest you query this person's prescription history at the IL-PDMP website if you require additional or updated information.

Following your review and assessment of the prescription data for this person, you should, as always, act according to your informed professional judgment.

We have provided this requested report in support of the program's mission to identify and inhibit the diversion of controlled substances in a manner that will not impede the appropriate utilization of these medications for legitimate medical purposes.

Sincerely,

Name TBD

Title TBD

DT Disp	Qty	Days	Drug Name	Dispenser	City	Prescriber
2012-11-26	30		HYDROCODONE BITACETAMINOPHEN	CVS/PHARMACY #08632	DECATUR	LEE
2012-11-19	10		TESTOSTERONE CYPIONATE	CVS/PHARMACY #08632	DECATUR	YETURU
2012-11-24	20		HYDROCODONE BITACETAMINOPHEN	CVS/PHARMACY #08632	DECATUR	REYES

# Production

The screenshot displays a medical software interface for a patient named John Smith. The interface includes a navigation menu on the left, a top toolbar with a 'PMP' button highlighted in red, and a main content area with three sections: Patient Details, Medication Details, and Pharmacy Details. A red arrow points to the 'PMP' button, and another red arrow points to the 'Patient Details' section. Below the main content area, a browser window shows search results for 'HYDROCODON-ACETAMINOPHEN' on PubMed Health, with a red arrow pointing to the search results.

**PMP Patient Lookup**

Last Name	First Name	Address	City	State	Postal Code	Birth Date	Sex	Date Filled	Label Name	Prescriber
SMITH	JOHN			IL		2015-2-3	M		HYDROCODON-ACETAMINOPHEN	
SMITH	JOHN			IL		2015-1-19	M		ZOLPIDEM TARTRATE	
SMITH	JOHN			IL		2014-12-30	M		GUAIFENESIN-CODEINE	

**Patient Details**

Last Name	SMITH
First Name	JOHN
Address	
City	
State	IL
Postal Code	
Birth Date	
Sex	M

**Medication Details**

Date Filled	2015-2-3
Strength	5MG-325MG
Qty / Days Supply	20/5
Payment Type	Commercial Insurance
Pharmacy	
Prescriber	
Refills	00
Org Street	

**Pharmacy Details**

Org State	IL
Org Zip	62896
Org Phone	(618) 937-2416
Prescriber City	DANVILLE
Prescriber State	IL
Prescription Number	142646437
Written Date	2015-2-3
Schedule	2
NDC Number	00406012305

**Search Results - HYDROCODON-ACETAMINOPHEN - National Library of Medicine - PubMed Health - Microsoft Internet Explorer provided**

U.S. National Library of Medicine - The World's Largest Medical Library

Search Results - HYDROCODON-ACETAMINOPHEN

Did you mean: [hydrocodone acetaminophen](#) (14 items)

**About - Hydrocodone/Acetaminophen (By mouth)**  
Treats pain. This medicine contains a narcotic pain reliever.  
Uses•Side effects•Latest evidence reviews•Research summaries for consumers•Brand names

**Results: 14**  
[Drug Class Review: Drugs for Fibromyalgia: Final Original Report \[Internet\]](#)



# **Additional Info**





# Confirmation of Active Engagement

- Request confirmation of active engagement status during Promoting Interoperability (formerly “Meaningful Use”) reporting period
- Email [DHS.PMP@Illinois.gov](mailto:DHS.PMP@Illinois.gov) with:
  - Subject line: “Confirmation for Promoting Interoperability”
  - Body of email:
    - Your organization name and HL7 ID (starts with “777” or “888”)
    - Your provider name(s)
    - Reporting period



# eMIPP Attestation

- Report under MU-Public Health Measures tab
- Open Measure 3: Specialized Registry Reporting
- Select “No” to Specialty Registry Availability Verification unless you are claiming exclusions from all other public health measures
- Select “No” to Exclusion and “Yes” to Compliance
- Choose ILPMP under Registry Details
- Upload confirmation of active engagement into Upload Document

# eMIPP Attestation

▼ Measure 3 : Specialized Registry Reporting !

The EP is in active engagement to submit data to a specialized registry. Selecting any exclusion below will exclude the whole measure.

— Specialty Registry Availability Verification —

Verification applies to you?  Yes  No

**Specialty Registry Availability Verification:**

- By selecting Yes, you indicate that you have performed due diligence of specialty registry availability verification with State and specialty society.
- By selecting No, you indicate that you did not perform due diligence of specialty registry availability verification with State and specialty society.

— Measure 3.1 —

— Exclusion —

Exclusion applies to you?  Yes  No

**Any EP meeting at least one of the following criteria may be excluded from the specialized registry reporting measure if the EP:**

- Does not diagnose or treat any disease or condition associated with, or collect relevant data that is collected by, a specialized registry in their jurisdiction during the EHR reporting period;
- Operates in a jurisdiction for which no specialized registry is capable of accepting electronic registry transactions in the specific standards required to meet the CEHRT definition at the start of the EHR reporting period; or
- Operates in a jurisdiction where no specialized registry for which the EP is eligible has declared readiness to receive electronic registry transactions at the beginning of the EHR reporting period.

— Compliance —

Active engagement with Specialized Registry?  Yes  No

EPs must attest YES to being in active engagement to submit data to a specialized registry.

— Registry Details —

Select Registry: Illinois Prescription Monitoring Program (ILPMP) ▼

# eMIPP Attestation

**Upload Document** ✕

Please select document to upload, select document type, add a descriptive comment and click on "Upload"

[Click Browse to Upload File](#)

**File Name: \***  No file chosen

**File Type: \*** Public Health - Specialized Registry ▼

**File Description: \***

**Rich Text Editor:**  
B I U S P [List Icon] [Link Icon] [Image Icon] [Text Color Icon] [Background Color Icon] 10 [Font Size Icon] X<sub>2</sub> X<sup>2</sup> [Undo Icon] [Redo Icon] [Print Icon] [Close Icon]

Confirmation email from [JLMP](#)

# Stage 3 Requirement

- Phased out “specialized registry” measure; ILPMP will fall under Measure 4: Public Health Registry
- For Measure 4, a provider may count a specialized registry (such as prescription drug monitoring) if the provider achieved Active Engagement Option 3: Production in a prior year
- Must attest to *active engagement option 3* with ILPMP in 2018 (or earlier) in order to use it for Stage 3 public health reporting in 2019



# Medicare QPP + MIPS

- Medicare MIPS has a “Promoting Interoperability” category
- MIPS “Promoting Interoperability” has an optional public health reporting measure
- Active engagement with ILPMP can earn MIPS bonus points



# Web References

- [PDMP Assist FAQ](#)
- [Illinois Prescription Drug Monitoring Program website](#)
- [Illinois Public Act 100-0564](#)
- [LogiCoy PDMP](#)
- [Demonstration of PDMP integration with AllScripts](#)

Questions??



# Contact Information



CHICAGO HEALTH INFORMATION TECHNOLOGY  
REGIONAL EXTENSION CENTER

Email: [info@chitrec.org](mailto:info@chitrec.org)

Phone: 312 503-2986



ILLINOIS HEALTH INFORMATION TECHNOLOGY  
REGIONAL EXTENSION CENTER

Email: [info@ilhitrec.org](mailto:info@ilhitrec.org)

Phone: 815-753-5900



**Illinois Prescription Monitoring  
Program**

[Prescription Monitoring](#)  
401 North Fourth Street  
Springfield, IL 62702

Fax: (217) 557-7975  
Phone: (217) 524-1311